Robert W. Baird Cuts Alto Neuroscience (NYSE:ANRO) Price Target to $38.00

Alto Neuroscience (NYSE:ANRO) had its price target trimmed by Robert W. Baird from $41.00 to $38.00 in a research report sent to investors on Thursday morning,Benzinga reports. The brokerage currently has an outperform rating on the stock.

A number of other research firms have also recently weighed in on ANRO. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Alto Neuroscience in a report on Monday, December 29th. BTIG Research boosted their target price on shares of Alto Neuroscience from $27.00 to $28.00 and gave the company a “buy” rating in a research note on Tuesday, February 17th. Jefferies Financial Group restated a “buy” rating and issued a $35.00 target price on shares of Alto Neuroscience in a research report on Monday, March 16th. JonesTrading dropped their price target on shares of Alto Neuroscience from $49.00 to $44.00 and set a “buy” rating on the stock in a research note on Thursday. Finally, Wedbush cut their price target on Alto Neuroscience from $22.00 to $21.00 and set a “neutral” rating on the stock in a report on Thursday. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $35.14.

Alto Neuroscience Stock Down 0.5%

Shares of Alto Neuroscience stock opened at $21.57 on Thursday. The stock has a market capitalization of $688.95 million, a price-to-earnings ratio of -9.89 and a beta of 2.01. Alto Neuroscience has a twelve month low of $1.60 and a twelve month high of $25.17. The company has a current ratio of 15.69, a quick ratio of 15.69 and a debt-to-equity ratio of 0.12. The business’s 50 day simple moving average is $19.27 and its 200-day simple moving average is $14.88.

Alto Neuroscience (NYSE:ANRO) last issued its earnings results on Monday, March 16th. The company reported ($0.45) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.11. Equities research analysts forecast that Alto Neuroscience will post -2.54 earnings per share for the current year.

Institutional Investors Weigh In On Alto Neuroscience

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Bridgeway Capital Management LLC lifted its holdings in Alto Neuroscience by 85.9% in the second quarter. Bridgeway Capital Management LLC now owns 54,100 shares of the company’s stock worth $119,000 after purchasing an additional 25,000 shares during the period. Invesco Ltd. acquired a new position in Alto Neuroscience during the 1st quarter valued at about $67,000. Commodore Capital LP bought a new stake in shares of Alto Neuroscience during the 4th quarter worth about $32,453,000. Perceptive Advisors LLC raised its position in shares of Alto Neuroscience by 1,048.5% during the 4th quarter. Perceptive Advisors LLC now owns 1,784,393 shares of the company’s stock worth $31,762,000 after buying an additional 1,629,027 shares in the last quarter. Finally, 683 Capital Management LLC acquired a new stake in shares of Alto Neuroscience in the 4th quarter worth approximately $1,153,000.

Key Alto Neuroscience News

Here are the key news stories impacting Alto Neuroscience this week:

• Positive Sentiment: Several brokers reaffirmed buy/outperform views and high upside potential — HC Wainwright kept a Buy and a $50 price target (large upside vs. current price). Article Title
• Positive Sentiment: Chardan Capital reaffirmed a Buy with a $30 target, signaling continued analyst conviction despite the trial miss. Article Title
• Positive Sentiment: JonesTrading kept a Buy rating while trimming its target from $49 to $44 — still implying substantial upside from current levels. Article Title
• Positive Sentiment: Robert W. Baird cut its target to $38 but left an Outperform rating — another signal that some analysts view the selloff as a buying opportunity. Article Title
• Neutral Sentiment: Wedbush trimmed its target to $21 and moved to a Neutral rating, reflecting a more cautious stance but only a small target cut vs. price. Article Title
• Neutral Sentiment: Company fundamentals: recent quarter slightly beat EPS expectations, Alto has a market cap near $689M, high liquidity metrics (current/quick ratio ~15.7) and high beta (~2.0) — factors that increase volatility but limit near-term solvency concerns.
• Negative Sentiment: Trial failure: Alto’s schizophrenia study missed its primary endpoint; that clinical setback is the primary driver of selling pressure and re-pricing. Article Title
• Negative Sentiment: Market reaction/coverage: multiple headlines highlight a sharp drop and pre-market weakness after the study news, amplifying volatility and headline-driven flows. Article Title
• Negative Sentiment: Sentiment hit from coverage calling the result a “shocking miss,” which can accelerate short-term selling and make recovery dependent on management commentary, further data, or new catalysts. Article Title

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.